Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.3K

Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma

Bahareh Hassani1, Amirsajad Jafari2, Marjan Tavakkoli1

  • 1Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Biochemical and Biophysical Research Communications
|December 11, 2025
PubMed
Abstract

Insights

Combining olaparib, a PARP inhibitor, with doxorubicin or mitoxantrone shows synergistic effects against pancreatic cancer cells. This combination may offer a new therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC) patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer.
  • Poly (ADP-ribose) polymerase (PARP) inhibitors show promise in PDAC treatment.
  • PARP enzymes are critical for DNA repair pathways.

Purpose of the Study:

  • To evaluate the anticancer efficacy of olaparib combined with DNA-damaging agents against PDAC.
  • To assess combinations of olaparib with doxorubicin, mitoxantrone, oxaliplatin, and gemcitabine.
  • To investigate synergistic interactions in PDAC cell lines.

Main Methods:

  • MTT assays to determine growth inhibition.
  • CalcuSyn software for combination index (CI) calculation.
  • Spheroid, colony formation, Hoechst staining, DCFH-DA, and γH2AX assays were used.

Main Results:

  • Olaparib combined with doxorubicin or mitoxantrone showed synergistic effects (CI < 1).
  • These synergistic combinations significantly inhibited spheroid growth and clonogenic ability.
  • Synergy was linked to increased reactive oxygen species (ROS) and DNA damage.

Conclusions:

  • Combination of olaparib with doxorubicin or mitoxantrone demonstrates synergistic anticancer activity in PDAC cells.
  • This combination warrants further investigation as a potential therapeutic strategy for PDAC.
  • Preclinical data support the evaluation of this combination in clinical settings.
Keywords:
AnthracyclinesCombination therapyDNA damage responseFree radicalsIn vitro assayPARP inhibitors

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.3K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.7K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K